Synta is currently enrolling patients in a Phase 2 single-arm, open-label, single-agent study of STA-9090 in patients with stage IIIB or IV non-small cell lung cancer, with patient cohorts defined by the genetic profile of their tumors.
Geoffrey Shapiro, a co-principal investigator on the recently initiated Phase 2 trial for STA-9090 in NSCLC, said: “Results to date demonstrate that the Hsp90 inhibitor STA-9090 has greater potency compared to first-generation Hsp90 inhibitors, such as 17-AAG, in destabilizing critical oncoproteins and components of their signaling pathways, including EGFR, ERBB2 (HER2), BRAF and MET.
“In early trials, STA-9090 has shown promising signs of single-agent activity and an acceptable safety profile, without the severe liver and other toxicities observed with the first-generation Hsp90 inhibitors. These preclinical and early clinical results are encouraging and support the ongoing Phase 2 multicenter clinical study of STA-9090 in NSCLC.”
Vojo Vukovic, chief medical officer at Synta, said: “We are pleased to have STA-9090 presented as a leading Hsp90 inhibitor program in NSCLC at this major international lung cancer meeting. We are particularly encouraged that leading lung cancer investigators have shown a high level of interest in participating in our NSCLC clinical trial with STA-9090.”